QMed, Inc.
QMed, Inc. (QMED) Stock Competitors & Peer Comparison
See (QMED) competitors and their performances in Stock Market.
Peer Comparison Table: Medical - Specialties Industry
Detailed financial metrics including price, market cap, P/E ratio, and more.
| Symbol | Price | Change % | Market Cap | P/E Ratio | EPS | Dividend Yield |
|---|---|---|---|---|---|---|
| QMED | $0.00 | +0.00% | 17 | -0.00 | -$0.66 | N/A |
| BMXXY | $7.95 | -0.87% | 9.4B | 20.38 | $0.39 | +1.30% |
| EBOSY | $26.42 | +0.00% | 1.4B | 17.97 | $1.47 | +5.42% |
| AVNBF | $24.70 | +0.00% | 724M | 72.65 | $0.34 | +1.00% |
| EBRCZ | $0.42 | +0.00% | 316.1M | -3.53 | -$0.12 | N/A |
| XVIPY | $6.54 | +0.00% | 206M | N/A | N/A | N/A |
| TRXDW | $0.15 | -11.76% | 40.1M | N/A | N/A | N/A |
| ACIXF | $0.03 | -3.55% | 33.6M | -2.99 | -$0.01 | N/A |
| NVNBW | $0.01 | +0.00% | 141.5K | -0.00 | -$1.95 | N/A |
| GWPC | $0.00 | +0.00% | 52K | -0.01 | -$0.01 | N/A |
Stock Comparison
QMED vs BMXXY Comparison May 2026
QMED plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, QMED stands at 17. In comparison, BMXXY has a market cap of 9.4B. Regarding current trading prices, QMED is priced at $0.00, while BMXXY trades at $7.95.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
QMED currently has a P/E ratio of -0.00, whereas BMXXY's P/E ratio is 20.38. In terms of profitability, QMED's ROE is N/A, compared to BMXXY's ROE of +0.10%. Regarding short-term risk, QMED is less volatile compared to BMXXY. This indicates potentially lower risk in terms of short-term price fluctuations for QMED.Check BMXXY's competition here
QMED vs EBOSY Comparison May 2026
QMED plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, QMED stands at 17. In comparison, EBOSY has a market cap of 1.4B. Regarding current trading prices, QMED is priced at $0.00, while EBOSY trades at $26.42.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
QMED currently has a P/E ratio of -0.00, whereas EBOSY's P/E ratio is 17.97. In terms of profitability, QMED's ROE is N/A, compared to EBOSY's ROE of +0.06%. Regarding short-term risk, QMED is less volatile compared to EBOSY. This indicates potentially lower risk in terms of short-term price fluctuations for QMED.Check EBOSY's competition here
QMED vs AVNBF Comparison May 2026
QMED plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, QMED stands at 17. In comparison, AVNBF has a market cap of 724M. Regarding current trading prices, QMED is priced at $0.00, while AVNBF trades at $24.70.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
QMED currently has a P/E ratio of -0.00, whereas AVNBF's P/E ratio is 72.65. In terms of profitability, QMED's ROE is N/A, compared to AVNBF's ROE of +0.05%. Regarding short-term risk, QMED is less volatile compared to AVNBF. This indicates potentially lower risk in terms of short-term price fluctuations for QMED.Check AVNBF's competition here
QMED vs EBRCZ Comparison May 2026
QMED plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, QMED stands at 17. In comparison, EBRCZ has a market cap of 316.1M. Regarding current trading prices, QMED is priced at $0.00, while EBRCZ trades at $0.42.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
QMED currently has a P/E ratio of -0.00, whereas EBRCZ's P/E ratio is -3.53. In terms of profitability, QMED's ROE is N/A, compared to EBRCZ's ROE of -329.75%. Regarding short-term risk, QMED is less volatile compared to EBRCZ. This indicates potentially lower risk in terms of short-term price fluctuations for QMED.Check EBRCZ's competition here
QMED vs XVIPY Comparison May 2026
QMED plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, QMED stands at 17. In comparison, XVIPY has a market cap of 206M. Regarding current trading prices, QMED is priced at $0.00, while XVIPY trades at $6.54.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
QMED currently has a P/E ratio of -0.00, whereas XVIPY's P/E ratio is N/A. In terms of profitability, QMED's ROE is N/A, compared to XVIPY's ROE of +0.01%. Regarding short-term risk, QMED and XVIPY have similar daily volatility (0.00).Check XVIPY's competition here
QMED vs TRXDW Comparison May 2026
QMED plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, QMED stands at 17. In comparison, TRXDW has a market cap of 40.1M. Regarding current trading prices, QMED is priced at $0.00, while TRXDW trades at $0.15.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
QMED currently has a P/E ratio of -0.00, whereas TRXDW's P/E ratio is N/A. In terms of profitability, QMED's ROE is N/A, compared to TRXDW's ROE of -1.18%. Regarding short-term risk, QMED and TRXDW have similar daily volatility (0.00).Check TRXDW's competition here
QMED vs ACIXF Comparison May 2026
QMED plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, QMED stands at 17. In comparison, ACIXF has a market cap of 33.6M. Regarding current trading prices, QMED is priced at $0.00, while ACIXF trades at $0.03.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
QMED currently has a P/E ratio of -0.00, whereas ACIXF's P/E ratio is -2.99. In terms of profitability, QMED's ROE is N/A, compared to ACIXF's ROE of -1.04%. Regarding short-term risk, QMED and ACIXF have similar daily volatility (0.00).Check ACIXF's competition here
QMED vs NVNBW Comparison May 2026
QMED plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, QMED stands at 17. In comparison, NVNBW has a market cap of 141.5K. Regarding current trading prices, QMED is priced at $0.00, while NVNBW trades at $0.01.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
QMED currently has a P/E ratio of -0.00, whereas NVNBW's P/E ratio is -0.00. In terms of profitability, QMED's ROE is N/A, compared to NVNBW's ROE of -0.61%. Regarding short-term risk, QMED is less volatile compared to NVNBW. This indicates potentially lower risk in terms of short-term price fluctuations for QMED.Check NVNBW's competition here
QMED vs GWPC Comparison May 2026
QMED plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, QMED stands at 17. In comparison, GWPC has a market cap of 52K. Regarding current trading prices, QMED is priced at $0.00, while GWPC trades at $0.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
QMED currently has a P/E ratio of -0.00, whereas GWPC's P/E ratio is -0.01. In terms of profitability, QMED's ROE is N/A, compared to GWPC's ROE of N/A. Regarding short-term risk, QMED and GWPC have similar daily volatility (0.00).Check GWPC's competition here
QMED vs SXHHF Comparison May 2026
QMED plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, QMED stands at 17. In comparison, SXHHF has a market cap of 38.1K. Regarding current trading prices, QMED is priced at $0.00, while SXHHF trades at $0.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
QMED currently has a P/E ratio of -0.00, whereas SXHHF's P/E ratio is -0.01. In terms of profitability, QMED's ROE is N/A, compared to SXHHF's ROE of +1.13%. Regarding short-term risk, QMED is less volatile compared to SXHHF. This indicates potentially lower risk in terms of short-term price fluctuations for QMED.Check SXHHF's competition here
QMED vs DGCRF Comparison May 2026
QMED plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, QMED stands at 17. In comparison, DGCRF has a market cap of 21.5K. Regarding current trading prices, QMED is priced at $0.00, while DGCRF trades at $0.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
QMED currently has a P/E ratio of -0.00, whereas DGCRF's P/E ratio is 0.00. In terms of profitability, QMED's ROE is N/A, compared to DGCRF's ROE of -1.11%. Regarding short-term risk, QMED is less volatile compared to DGCRF. This indicates potentially lower risk in terms of short-term price fluctuations for QMED.Check DGCRF's competition here
QMED vs KKUR Comparison May 2026
QMED plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, QMED stands at 17. In comparison, KKUR has a market cap of 8.2K. Regarding current trading prices, QMED is priced at $0.00, while KKUR trades at $0.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
QMED currently has a P/E ratio of -0.00, whereas KKUR's P/E ratio is N/A. In terms of profitability, QMED's ROE is N/A, compared to KKUR's ROE of N/A. Regarding short-term risk, QMED is less volatile compared to KKUR. This indicates potentially lower risk in terms of short-term price fluctuations for QMED.Check KKUR's competition here
QMED vs SCIE Comparison May 2026
QMED plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, QMED stands at 17. In comparison, SCIE has a market cap of 4.9K. Regarding current trading prices, QMED is priced at $0.00, while SCIE trades at $0.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
QMED currently has a P/E ratio of -0.00, whereas SCIE's P/E ratio is -0.00. In terms of profitability, QMED's ROE is N/A, compared to SCIE's ROE of +0.51%. Regarding short-term risk, QMED and SCIE have similar daily volatility (0.00).Check SCIE's competition here
QMED vs OMRX Comparison May 2026
QMED plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, QMED stands at 17. In comparison, OMRX has a market cap of 4.7K. Regarding current trading prices, QMED is priced at $0.00, while OMRX trades at $0.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
QMED currently has a P/E ratio of -0.00, whereas OMRX's P/E ratio is N/A. In terms of profitability, QMED's ROE is N/A, compared to OMRX's ROE of -0.15%. Regarding short-term risk, QMED is less volatile compared to OMRX. This indicates potentially lower risk in terms of short-term price fluctuations for QMED.Check OMRX's competition here
QMED vs IBXG Comparison May 2026
QMED plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, QMED stands at 17. In comparison, IBXG has a market cap of 2K. Regarding current trading prices, QMED is priced at $0.00, while IBXG trades at $0.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
QMED currently has a P/E ratio of -0.00, whereas IBXG's P/E ratio is N/A. In terms of profitability, QMED's ROE is N/A, compared to IBXG's ROE of N/A. Regarding short-term risk, QMED is less volatile compared to IBXG. This indicates potentially lower risk in terms of short-term price fluctuations for QMED.Check IBXG's competition here
QMED vs DMSI Comparison May 2026
QMED plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, QMED stands at 17. In comparison, DMSI has a market cap of 1.9K. Regarding current trading prices, QMED is priced at $0.00, while DMSI trades at $0.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
QMED currently has a P/E ratio of -0.00, whereas DMSI's P/E ratio is N/A. In terms of profitability, QMED's ROE is N/A, compared to DMSI's ROE of -0.32%. Regarding short-term risk, QMED is less volatile compared to DMSI. This indicates potentially lower risk in terms of short-term price fluctuations for QMED.Check DMSI's competition here
QMED vs AAXT Comparison May 2026
QMED plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, QMED stands at 17. In comparison, AAXT has a market cap of 1.6K. Regarding current trading prices, QMED is priced at $0.00, while AAXT trades at $0.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
QMED currently has a P/E ratio of -0.00, whereas AAXT's P/E ratio is N/A. In terms of profitability, QMED's ROE is N/A, compared to AAXT's ROE of +0.54%. Regarding short-term risk, QMED and AAXT have similar daily volatility (0.00).Check AAXT's competition here
QMED vs XCRP Comparison May 2026
QMED plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, QMED stands at 17. In comparison, XCRP has a market cap of 1.5K. Regarding current trading prices, QMED is priced at $0.00, while XCRP trades at $0.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
QMED currently has a P/E ratio of -0.00, whereas XCRP's P/E ratio is N/A. In terms of profitability, QMED's ROE is N/A, compared to XCRP's ROE of -3.49%. Regarding short-term risk, QMED and XCRP have similar daily volatility (0.00).Check XCRP's competition here
QMED vs BMGP Comparison May 2026
QMED plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, QMED stands at 17. In comparison, BMGP has a market cap of 1.3K. Regarding current trading prices, QMED is priced at $0.00, while BMGP trades at $0.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
QMED currently has a P/E ratio of -0.00, whereas BMGP's P/E ratio is N/A. In terms of profitability, QMED's ROE is N/A, compared to BMGP's ROE of -0.50%. Regarding short-term risk, QMED is less volatile compared to BMGP. This indicates potentially lower risk in terms of short-term price fluctuations for QMED.Check BMGP's competition here
QMED vs IMRSQ Comparison May 2026
QMED plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, QMED stands at 17. In comparison, IMRSQ has a market cap of 626. Regarding current trading prices, QMED is priced at $0.00, while IMRSQ trades at $0.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
QMED currently has a P/E ratio of -0.00, whereas IMRSQ's P/E ratio is N/A. In terms of profitability, QMED's ROE is N/A, compared to IMRSQ's ROE of -1.30%. Regarding short-term risk, QMED is less volatile compared to IMRSQ. This indicates potentially lower risk in terms of short-term price fluctuations for QMED.Check IMRSQ's competition here
QMED vs STBV Comparison May 2026
QMED plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, QMED stands at 17. In comparison, STBV has a market cap of 471. Regarding current trading prices, QMED is priced at $0.00, while STBV trades at $0.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
QMED currently has a P/E ratio of -0.00, whereas STBV's P/E ratio is N/A. In terms of profitability, QMED's ROE is N/A, compared to STBV's ROE of -1.13%. Regarding short-term risk, QMED is less volatile compared to STBV. This indicates potentially lower risk in terms of short-term price fluctuations for QMED.Check STBV's competition here
QMED vs OMDD Comparison May 2026
QMED plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, QMED stands at 17. In comparison, OMDD has a market cap of 310. Regarding current trading prices, QMED is priced at $0.00, while OMDD trades at $0.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
QMED currently has a P/E ratio of -0.00, whereas OMDD's P/E ratio is N/A. In terms of profitability, QMED's ROE is N/A, compared to OMDD's ROE of N/A. Regarding short-term risk, QMED is less volatile compared to OMDD. This indicates potentially lower risk in terms of short-term price fluctuations for QMED.Check OMDD's competition here